- Conditions
- Marburg Hemorrhagic Fever
- Interventions
- AVI-7288, Placebo
- Drug · Other
- Lead sponsor
- Sarepta Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 1,613
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Muscular Dystrophies
- Interventions
- rAAV1.tMCK.human-alpha-sarcoglycan- First cohort, Genetic: rAAV1.tMCK.human-alpha-sarcoglycan- Second cohort
- Genetic
- Lead sponsor
- Nationwide Children's Hospital
- Other
- Eligibility
- 5 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Ankylosing Spondylitis
- Interventions
- ABY-035, Placebo
- Drug
- Lead sponsor
- Inmagene LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 15
- States / cities
- Glendale, Arizona • Canoga Park, California • Huntington Beach, California + 12 more
- Conditions
- Kidney Failure, Chronic Therapy; Hemodialysis
- Interventions
- soluble ferric pyrophosphate, Placebo
- Drug
- Lead sponsor
- Rockwell Medical Technologies, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Kalamazoo, Michigan
- Conditions
- Healthy
- Interventions
- DSM265, Placebo, Sporozoites, Infective mosquito bite
- Drug · Biological
- Lead sponsor
- Medicines for Malaria Venture
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Osteoarthritis, Knee
- Interventions
- PF-04191834, PF-04191834 placebo, Naproxen placebo, Naproxen
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 190 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 25
- States / cities
- Peoria, Arizona • Phoenix, Arizona • Anaheim, California + 20 more
- Conditions
- Healthy
- Interventions
- MEDI-559, Placebo
- Biological · Other
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 1 Month to 23 Months
- Enrollment
- 116 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2011
- U.S. locations
- 75
- States / cities
- Greenville, Alabama • Huntsville, Alabama • Mobile, Alabama + 62 more
- Conditions
- Glioma, Anaplastic Astrocytoma, Anaplastic Astro-oligodendroglioma, Glioblastoma
- Interventions
- autologous tumor lysate-pulsed DC vaccination, Tumor lysate-pulsed DC vaccination+0.2% resiquimod, Tumor-lysate pulsed DC vaccination +adjuvant polyICLC
- Biological
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2024
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Healthy
- Interventions
- PF-07976016, Placebo, Midazolam
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 117 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Peanut Allergies
- Interventions
- MY006 Low Dose, MY006 Mid Dose, MY006 High Dose, MY006 Selected Dose, Placebo (Vehicle)
- Drug
- Lead sponsor
- Mabylon AG
- Industry
- Eligibility
- 12 Years to 55 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 9
- States / cities
- Little Rock, Arkansas • Aurora, Colorado • Colorado Springs, Colorado + 6 more
- Conditions
- Solid Tumors
- Interventions
- AZD6094 200 mg, Placebo, Moxifloxacin
- Drug · Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 45 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Coccidioidomycosis
- Interventions
- Placebo, VT-1598
- Other · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Severe Sepsis
- Interventions
- AZD9773 (CytoFab), Placebo
- Drug · Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Newark, Delaware • Bay Pines, Florida + 23 more
- Conditions
- Atherosclerosis, Cardiovascular Disease
- Interventions
- MEDI6570, Placebo, Part B Placebo
- Biological
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 9
- States / cities
- Anniston, Alabama • Jacksonville, Florida • Miami, Florida + 6 more
- Conditions
- Healthy
- Interventions
- PRA052, Placebo
- Drug · Other
- Lead sponsor
- Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 96 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Lincoln, Nebraska
- Conditions
- Postoperative Pain
- Interventions
- HTX-011, Saline Placebo, Bupivicaine HCl, Ropivacaine
- Drug
- Lead sponsor
- Heron Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 285 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 24
- States / cities
- Mobile, Alabama • Sheffield, Alabama • Phoenix, Arizona + 13 more
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Erlotinib + Sorafenib, Erlotinib + Placebo
- Drug
- Lead sponsor
- SCRI Development Innovations, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 166 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 16
- States / cities
- Fort Myers, Florida • Gainesville, Georgia • Marietta, Georgia + 13 more
- Conditions
- Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Ovarian Cancer, Ovarian Serous Adenocarcinoma, Fallopian Tube Neoplasms, Fallopian Tube Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Peritoneal Cancer, Peritoneal Carcinoma, Peritoneal Neoplasms
- Interventions
- Oregovomab, Paclitaxel, Carboplatin, Placebo
- Biological · Drug
- Lead sponsor
- CanariaBio Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 615 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 81
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Concord, California + 70 more
- Conditions
- Pulmonary Arterial Hypertension, Hypertension, Pulmonary
- Interventions
- Frespaciguat, Placebo to Frespaciguat
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 168 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 26
- States / cities
- La Jolla, California • Sacramento, California • San Francisco, California + 22 more
- Conditions
- Healthy Subjects
- Interventions
- STP707
- Drug
- Lead sponsor
- Sirnaomics
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Inflammation, Systemic Lupus Erythematosus
- Interventions
- NNC 0151-0000-0000, placebo
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Lake Success, New York
- Conditions
- Heart Failure
- Interventions
- CXL-1020, Placebo for CXL-1020 Cohort 1, Placebo for CXL-1020 Cohort 2, CXL-1020 Dose for Echo Cohort A, CXL-1020 Doses for Echo Cohort B
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Tustin, California
- Conditions
- Covid19-associated ARDS, Covid19, ARDS
- Interventions
- AV-001, Placebo
- Drug · Other
- Lead sponsor
- Vasomune Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Healthy
- Interventions
- YUQ-A1007 is a novel gut-enriched AhR agonist. This compound is undergoing preclinical development, and comprehensive nonclinical studies.
- Drug
- Lead sponsor
- Allianthera (Suzhou) Biopharmaceuticals Co., Ltd.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Anaheim, California